HRP20200529T1 - Postupci i pripravci za modificiranje ciljnog lokusa - Google Patents

Postupci i pripravci za modificiranje ciljnog lokusa Download PDF

Info

Publication number
HRP20200529T1
HRP20200529T1 HRP20200529TT HRP20200529T HRP20200529T1 HR P20200529 T1 HRP20200529 T1 HR P20200529T1 HR P20200529T T HRP20200529T T HR P20200529TT HR P20200529 T HRP20200529 T HR P20200529T HR P20200529 T1 HRP20200529 T1 HR P20200529T1
Authority
HR
Croatia
Prior art keywords
cell
polynucleotide
nucleic acid
nuclease
acid sequence
Prior art date
Application number
HRP20200529TT
Other languages
English (en)
Inventor
Wojtek Auerbach
David Frendewey
Gustavo Droguett
Anthony Gagliardi
Junko Kuno
David M. Valenzuela
Original Assignee
Regeneron Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharmaceuticals, Inc. filed Critical Regeneron Pharmaceuticals, Inc.
Publication of HRP20200529T1 publication Critical patent/HRP20200529T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/64—General methods for preparing the vector, for introducing it into the cell or for selecting the vector-containing host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • A01K2267/035—Animal model for multifactorial diseases
    • A01K2267/0387—Animal model for diseases of the immune system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (18)

1. Postupak za serijsku modifikaciju ciljnog lokusa u ćeliji, naznačen time što sadrži: (a) osiguravanje ćelije koja sadrži ciljni lokus, pri čemu ciljni lokus sadrži polinukleotid koji kodira prvi selekcijski marker koji je operativno povezan sa prvim promotorom i koji sadrži prvo mjesto za prepoznavanje za prvo sredstvo nukleaze, pri čemu je prvo mjesto za prepoznavanje nukleaze smješteno u kodirajućoj regiji prvog selekcijskog markera ili bilo kojoj ne-protein-kodirajućoj regiji prvog selekcijskog markera, izborno pri čemu je ciljni lokus u genomu ćelije ili je smješten u vektoru u ćeliji; (b) uvođenje u ćeliju: (i) prvog sredstva nukleaze, pri čemu prvo sredstvo nukleaze izaziva zarez ili dvolančani prekid na prvom mjestu za prepoznavanje nukleaze, čime se narušava ekspresija ili aktivnost prvog selekcijskog markera; i (ii) prvog vektora koji ciljno djeluje koji sadrži prvi umetnuti polinukleotid omeđen sa bočnih strana prvom homolognom granom koja odgovara prvom ciljnom mjestu smještenom u ciljnom lokusu i drugom homolognom granom koja odgovara drugom ciljnom mjestu smještenom u ciljnom lokusu, pri čemu prvi umetnuti polinukleotid sadrži: (I) prvi polinukleotid od interesa; i (II) polinukleotid koji kodira drugi selekcijski marker koji je operativno povezan sa drugim promotorom i koji sadrži drugo mjesto za prepoznavanje nukleaze za drugo sredstvo nukleaze, pri čemu su prvi selekcijski marker i drugi selekcijski marker različiti, pri čemu je prvo sredstvo nukleaze različito od drugog sredstva nukleaze, i pri čemu je drugo mjesto za prepoznavanje nukleaze smješteno u kodirajućoj regiji drugog selekcijskog markera ili bilo kojoj ne-protein-kodirajućoj regiji drugog selekcijskog markera; (c) identificiranje modificirane ćelije koja sadrži prvi umetnuti polinukleotid na ciljnom lokusu, pri čemu modificirana ćelija ima aktivnost drugog selekcijskog markera, ali nema aktivnost prvog selekcijskog markera, izborno pri čemu se identificiranje vrši putem testa modifikacije alela (MOA); (d) uvođenje u modificiranu ćeliju: (i) drugog sredstva nukleaze, pri čemu drugo sredstvo nukleaze izaziva zarez ili dvolančani prekid na drugom mjestu za prepoznavanje nukleaze, čime se narušava ekspresija ili aktivnost drugog selekcijskog markera; i (ii) drugog vektora koji ciljno djeluje koji sadrži drugi umetnuti polinukleotid omeđen sa bočnih strana trećom homolognom granom koja odgovara trećem ciljnom mjestu smještenom u ciljnom lokusu i četvrtom homolognom granom koja odgovara četvrtom ciljnom mjestu smještenom u ciljnom lokusu, pri čemu drugi umetnuti polinukleotid sadrži: (I) drugi polinukleotid od interesa; i (II) polinukleotid koji kodira treći selekcijski marker koji je operativno povezan sa trećim promotorom koji je aktivan u ćeliji i koji sadrži treće mjesto za prepoznavanje nukleaze za treće sredstvo nukleaze, pri čemu su prvi selekcijski marker i treći selekcijski marker identični, i pri čemu je treće mjesto za prepoznavanje nukleaze identično prvom mjestu za prepoznavanje nukleaze i različito je od drugog mjesta za prepoznavanje nukleaze, i prvo sredstvo nukleaze i treće sredstvo nukleaze identični su jedno drugome i različiti su od drugog sredstva nukleaze; i (e) identificiranje najmanje jedne ćelije koja sadrži drugi umetnuti polinukleotid integriran u ciljni lokus, izborno pri čemu se identificiranje vrši putem testa modifikacije alela (MOA).
2. Postupak prema patentnom zahtjevu 1, naznačen time što korak identificiranja (c) sadrži: (i) uzgajanje ćelije pod uvjetima koji omogućavaju identificiranje ćelija koje nemaju aktivnost prvog selekcijskog markera; ili (ii) identificiranje najmanje jedne ćelije koja sadrži prvi umetnuti polinukleotid integriran u prvo i drugo ciljno mjesto; i/ili pri čemu korak identificiranja (e) sadrži: (i) uzgajanje ćelije pod uvjetima koji omogućavaju identificiranje ćelija koje nemaju aktivnost drugog selekcijskog markera; ili (ii) identificiranje najmanje jedne ćelije koja sadrži drugi umetnuti polinukleotid integriran u treće i četvrto ciljno mjesto.
3. Postupak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što je polinukleotid koji kodira drugi selekcijski marker u modificiranoj ćeliji u koraku (c) omeđen sa bočnih strana trećim ciljnim mjestom i četvrtim ciljnim mjestom.
4. Postupak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što prvi, drugi, ili treći selekcijski marker daje rezistenciju na antibiotik, izborno pri čemu antibiotik sadrži G418, higromicin, blasticidin, neomicin, ili puromicin, ili pri čemu je prvi, drugi, ili treći selekcijski marker operativno povezan sa inducibilnim promotorom, i ekspresija selekcijskog markera je toksična za ćeliju, izborno pri čemu prvi, drugi, ili treći selekcijski marker sadrži hipoksantin-guanin fosforiboziltransferazu (HGPRT) ili timidin kinazu Herpes simplex virusa (HSV-TK).
5. Postupak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što je ćelija eukariotska ćelija, izborno pri čemu je eukariotska ćelija ćelija sisavca, izborno pri čemu je ćelija sisavca: (a) ćelija ne-ljudskog sisavca; (b) pluripotentna ćelija; (c) ljudski izazvana pluripotentna matična ćelija; (d) ljudski fibroblast; ili (e) ćelija glodavca.
6. Postupak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što je ćelija embrionalna matična (ES) ćelija miša ili ES ćelija štakora.
7. Postupak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što kombinirana uporaba prvog vektora koji ciljno djeluje sa prvim sredstvom nukleaze rezultira povećanom efikasnošću ciljnog djelovanja u usporedbi sa uporabom samo prvog vektora koji ciljno djeluje, izborno pri čemu je efikasnost ciljnog djelovanja prvog vektora koji ciljno djeluje povećana najmanje dvostruko u usporedbi sa uporabom samo prvog vektora koji ciljno djeluje.
8. Postupak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što prvo sredstvo nukleaze, drugo sredstvo nukleaze, ili treće sredstvo nukleaze: (a) sadrži polinukleotid koji kodira sredstvo nukleaze, pri čemu je polinukleotid sadržan u kaseti ekspresije i operativno je povezan sa kondicionalnim promotorom, inducibilnim promotorom, konstitutivnim promotorom, ili tkivno-specifičnim promotorom; (b) je iRNK koja kodira nukleazu; (c) je cinčani prst nukleaze (ZFN); (d) je efektorska nukleaza slična aktivatoru transkripcije (TALEN); (e) je meganukleaza; ili (f) je okupljena kratkim palindromskim ponavljanjima na jednakim razmacima (CRISPR)-povezan (Cas) protein i vodeća RNK (gRNA).
9. Postupak prema patentnom zahtjevu 8, naznačen time što je prvo sredstvo nukleaze, drugo sredstvo nukleaze, ili treće sredstvo nukleaze Cas protein i vodeća RNK, pri čemu je Cas protein Cas9, i pri čemu vodeća RNK (gRNA) sadrži: (a) CRISPR RNK (crRNA) koja cilja prvo, drugo, ili treće mjesto za prepoznavanje, pri čemu je prvo, drugo, ili treće mjesto za prepoznavanje neposredno omeđeno sa bočnih strana protorazmaknice susjednog motiva (PAM) sekvencom. (b) trans-aktivirajuću CRISPR RNK (tracrRNA); izborno pri čemu ciljni lokus sadrži nukleotidnu sekvencu SEQ ID NO: 1; i izborno pri čemu gRNA sadrži himernu RNK koja ima sekvencu nukleinske kiseline SEQ ID NO: 2 ili SEQ ID NO: 3 ili tracrRNA koja sadrži SEQ ID NO: 7 ili SEQ ID NO: 8.
10. Postupak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što: (a) prvo ciljno mjesto i drugo ciljno mjesto su neposredno pored prvog mjesta za prepoznavanje nukleaze; (b) prvo ciljno mjesto i drugo ciljno mjesto su oko 10 nukleotida do oko 14 kb od prvog mjesta za prepoznavanje nukleaze; (c) treće ciljno mjesto i četvrto ciljno mjesto su neposredno pored drugog mjesta za prepoznavanje nukleaze; ili (d) treće ciljno mjesto i četvrto ciljno mjesto su oko 10 nukleotida do oko 14 kb od drugog mjesta za prepoznavanje nukleaze.
11. Postupak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što: (a) ukupan zbroj prve homologne grane i druge homologne grane je najmanje oko 10 kb ili je svaka od prve i druge homologne grane u opsegu od oko 5 kb do oko 100 kb; i/ili (b) ukupan zbroj treće homologne grane i četvrte homologne grane je najmanje oko 10 kb ili je svaka od treće i četvrte homologne grane u opsegu od oko 5 kb do oko 100 kb; i/ili (c) prvi vektor koji ciljno djeluje je najmanje oko 10 kb ili je od oko 20 kb do oko 300 kb; i/ili (d) drugi vektor koji ciljno djeluje je najmanje oko 10 kb ili je od oko 20 kb do oko 300 kb; i/ili (e) prvi umetnuti polinukleotid dugačak je u opsegu od oko 5 kb do oko 300 kb; i/ili (f) drugi umetnuti polinukleotid dugačak je u opsegu od oko 5 kb do oko 300 kb.
12. Postupak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što: (a) integracija prvog umetnutog polinukleotida u ciljni lokus rezultira knockout-om, knock-in-om, točkastom mutacijom, zamjenom domena, zamjenom egzona, zamjenom introna, zamjenom regulatorne sekvence, zamjenom gena, ili njihovom kombinacijom; i/ili (b) integracija drugog umetnutog polinukleotida u ciljni lokus rezultira knockout-om, knock-in-om, točkastom mutacijom, zamjenom domena, zamjenom egzona, zamjenom introna, zamjenom regulatorne sekvence, zamjenom gena, ili njihovom kombinacijom.
13. Postupak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što: (a) prvi polinukleotid od interesa sadrži ljudski polinukleotid, sekvencu nukleinske kiseline koja je homologna ili ortologna sekvenci nukleinske kiseline u genomu ćelije, ili sekvencu egzogene nukleinske kiseline, izborno pri čemu prvi polinukleotid od interesa sadrži: (i) regiju alfa lokusa T ćelijskog receptora, izborno pri čemu prvi polinukleotid od interesa sadrži najmanje jedan segment gena varijabilne regije i/ili segment gena povezujuće regije alfa lokusa T ćelijskog receptora; ili (ii) nereorganizranu sekvencu nukleinske kiseline varijabilne regije teškog lanca ljudskog imunoglobulina koja je operativno povezana sa sekvencom nukleinske kiseline konstantne regije teškog lanca imunoglobulina; i/ili (b) drugi polinukleotid od interesa sadrži ljudski polinukleotid, sekvencu nukleinske kiseline koja je homologna ili ortologna sekvenci nukleinske kiseline u genomu ćelije, ili sekvencu egzogene nukleinske kiseline, izborno pri čemu drugi polinukleotid od interesa sadrži: (i) regiju alfa lokusa T ćelijskog receptora, izborno pri čemu drugi polinukleotid od interesa sadrži najmanje jedan segment gena varijabilne regije i/ili segment gena povezujuće regije alfa lokusa T ćelijskog receptora; ili (ii) nereorganiziranu sekvencu nukleinske kiseline varijabilne regije teškog lanca ljudskog imunoglobulina koja je operativno povezana sa sekvencom nukleinske kiseline konstantne regije teškog lanca imunoglobulina.
14. Postupak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što: (a) prvi polinukleotid od interesa i/ili drugi polinukleotid od interesa sadrži najmanje jedan alel bolesti; (b) prvi polinukleotid od interesa i/ili drugi polinukleotid od interesa sadrži sekvencu genske nukleinske kiseline koja kodira amino-kiselinsku sekvencu varijabilne regije teškog lanca ljudskog imunoglobulina; ili (c) prvi polinukleotid od interesa i/ili drugi polinukleotid od interesa sadrži sekvencu genske nukleinske kiseline koja kodira amino-kiselinsku sekvencu varijabilne regije lakog lanca ljudskog imunoglobulina, izborno pri čemu: (i) sekvenca genske nukleinske kiseline sadrži nereorganiziranu sekvencu nukleinske kiseline varijabilne regije λ i/ili κ lakog lanca; ili (ii) sekvenca genske nukleinske kiseline sadrži reorganiziranu sekvencu nukleinske kiseline varijabilne regije λ i/ili κ lakog lanca.
15. Postupak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što: (a) ciljni lokus sadrži lokus imunoglobulina; ili (b) ciljni lokus sadrži lokus T ćelijskog receptora, izborno pri čemu je lokus T ćelijskog receptora alfa lokus T ćelijskog receptora.
16. Postupak prema bilo kojem prethodnom patentnom zahtjevu, naznačen time što prvo sredstvo nukleaze, drugo sredstvo nukleaze, i treće sredstvo nukleaze su svaki Cas protein i vodeća RNK, i pri čemu je vodeća RNK (gRNA) specifična za gen za rezistenciju na higromicin ili neomicin.
17. Postupak prema patentnom zahtjevu 16, naznačen time što je gRNA specifična za gen za rezistenciju na neomicin kodirana nukleinskom kiselinom koja sadrži nukleotidnu sekvencu iznijetu u SEQ ID NO: 13, 14, 15, ili 16, ili pri čemu je gRNA specifična za gen za rezistenciju na higromicin kodirana nukleinskom kiselinom koja sadrži nukleotidnu sekvencu iznijetu u SEQ ID NO: 17, 18, 19, ili 20.
18. Postupak prema patentnom zahtjevu 17, naznačen time što: (a) prva gRNA kodirana je nukleinskom kiselinom koja sadrži nukleotidnu sekvencu iznijetu u SEQ ID NO: 13, 14, 15, ili 16, i druga gRNA kodirana je nukleinskom kiselinom koja sadrži nukleotidnu sekvencu iznijetu u SEQ ID NO: 17, 18, 19, ili 20; ili (b) prva gRNA kodirana je nukleinskom kiselinom koja sadrži nukleotidnu sekvencu iznijetu u SEQ ID NO: 17, 18, 19, ili 20, i druga gRNA kodirana je nukleinskom kiselinom koja sadrži nukleotidnu sekvencu iznijetu u SEQ ID NO: 13, 14, 15, ili 16.
HRP20200529TT 2014-06-06 2015-06-05 Postupci i pripravci za modificiranje ciljnog lokusa HRP20200529T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462008832P 2014-06-06 2014-06-06
US201462017916P 2014-06-27 2014-06-27
EP15729724.3A EP3152312B1 (en) 2014-06-06 2015-06-05 Methods and compositions for modifying a targeted locus
PCT/US2015/034503 WO2015188109A1 (en) 2014-06-06 2015-06-05 Methods and compositions for modifying a targeted locus

Publications (1)

Publication Number Publication Date
HRP20200529T1 true HRP20200529T1 (hr) 2020-09-04

Family

ID=53404960

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20200529TT HRP20200529T1 (hr) 2014-06-06 2015-06-05 Postupci i pripravci za modificiranje ciljnog lokusa

Country Status (25)

Country Link
US (4) US10106820B2 (hr)
EP (2) EP3708671B1 (hr)
JP (2) JP6688231B2 (hr)
KR (1) KR102374379B1 (hr)
CN (2) CN113215196B (hr)
AU (1) AU2015269187B2 (hr)
BR (1) BR112016028564A2 (hr)
CA (1) CA2950173C (hr)
CY (1) CY1122897T1 (hr)
DK (1) DK3152312T3 (hr)
ES (2) ES3019688T3 (hr)
HR (1) HRP20200529T1 (hr)
HU (1) HUE049776T2 (hr)
IL (1) IL249042B (hr)
LT (1) LT3152312T (hr)
MX (1) MX385689B (hr)
NZ (1) NZ727481A (hr)
PL (1) PL3152312T3 (hr)
PT (1) PT3152312T (hr)
RS (1) RS60359B1 (hr)
RU (1) RU2704283C9 (hr)
SG (2) SG10201913804WA (hr)
SI (1) SI3152312T1 (hr)
SM (1) SMT202000264T1 (hr)
WO (1) WO2015188109A1 (hr)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2853829C (en) 2011-07-22 2023-09-26 President And Fellows Of Harvard College Evaluation and improvement of nuclease cleavage specificity
AU2013251558B2 (en) 2012-04-25 2019-01-03 Regeneron Pharmaceuticals, Inc. Nuclease-mediated targeting with large targeting vectors
CN109913495B (zh) 2013-02-20 2022-11-25 瑞泽恩制药公司 大鼠的遗传修饰
SI2986729T1 (sl) 2013-04-16 2019-02-28 Regeneron Pharmaceuticals, Inc. Ciljana sprememba genoma podgane
US9163284B2 (en) 2013-08-09 2015-10-20 President And Fellows Of Harvard College Methods for identifying a target site of a Cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
US9737604B2 (en) 2013-09-06 2017-08-22 President And Fellows Of Harvard College Use of cationic lipids to deliver CAS9
US9322037B2 (en) 2013-09-06 2016-04-26 President And Fellows Of Harvard College Cas9-FokI fusion proteins and uses thereof
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
CN110951779B (zh) 2013-12-11 2024-04-16 瑞泽恩制药公司 用于靶向修饰基因组的方法和组合物
EP3460063B1 (en) 2013-12-11 2024-03-13 Regeneron Pharmaceuticals, Inc. Methods and compositions for the targeted modification of a genome
US20150166985A1 (en) 2013-12-12 2015-06-18 President And Fellows Of Harvard College Methods for correcting von willebrand factor point mutations
DK3152312T3 (da) 2014-06-06 2020-04-06 Regeneron Pharma Fremgangsmåder og sammensætninger til modifikation af et mållocus
JP6752158B2 (ja) 2014-06-26 2020-09-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 標的化された遺伝子修飾のための方法及び組成物、並びに使用方法
EP3177718B1 (en) 2014-07-30 2022-03-16 President and Fellows of Harvard College Cas9 proteins including ligand-dependent inteins
ES2741387T3 (es) 2014-10-15 2020-02-10 Regeneron Pharma Métodos y composiciones para generar o mantener células pluripotentes
ES3013183T3 (en) 2014-11-21 2025-04-11 Regeneron Pharma Methods for targeted genetic modification using paired guide rnas
CN107208113A (zh) 2014-12-19 2017-09-26 瑞泽恩制药公司 用于通过单步多重靶向进行靶向遗传修饰的方法和组合物
ES2768984T3 (es) 2015-10-05 2020-06-24 Prec Biosciences Inc Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas
IL287319B2 (en) * 2015-10-05 2023-02-01 Prec Biosciences Inc Genetically-modified cells comprising a modified human t cell receptor alpha constant region gene
SG10202104041PA (en) 2015-10-23 2021-06-29 Harvard College Nucleobase editors and uses thereof
AU2017230011A1 (en) * 2016-03-11 2018-09-27 2Seventy Bio, Inc. Genome edited immune effector cells
CA3017678A1 (en) * 2016-04-04 2017-10-12 Eth Zurich Mammalian cell line for protein production and library generation
PT4180519T (pt) 2016-04-15 2025-09-04 Memorial Sloan Kettering Cancer Center Células t transgénicas e composições de células t que expressam um recetor antigénico quimérico e métodos relacionados
RU2745563C2 (ru) 2016-05-20 2021-03-29 Регенерон Фармасьютикалс, Инк. Способы преодоления иммунологической толерантности с использованием множества направляющих рнк
RS66700B1 (sr) 2016-06-03 2025-05-30 Regeneron Pharma Glodari koji eksprimiraju egzogenu terminalnu dezoksinukleotidil transferazu
CN107513538A (zh) * 2016-06-17 2017-12-26 北京大学 基因敲除方法
US20180004537A1 (en) 2016-07-01 2018-01-04 Microsoft Technology Licensing, Llc Molecular State Machines
US11359234B2 (en) 2016-07-01 2022-06-14 Microsoft Technology Licensing, Llc Barcoding sequences for identification of gene expression
US10669558B2 (en) 2016-07-01 2020-06-02 Microsoft Technology Licensing, Llc Storage through iterative DNA editing
EP3494215A1 (en) 2016-08-03 2019-06-12 President and Fellows of Harvard College Adenosine nucleobase editors and uses thereof
CN109804066A (zh) 2016-08-09 2019-05-24 哈佛大学的校长及成员们 可编程cas9-重组酶融合蛋白及其用途
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
AU2017342543B2 (en) 2016-10-14 2024-06-27 President And Fellows Of Harvard College AAV delivery of nucleobase editors
SI3766343T1 (sl) 2016-11-04 2022-06-30 Regeneron Pharmaceuticals, Inc. Nehumane živali z modificiranim lokusom lahke verige lambda imunoglobulina
WO2018119359A1 (en) 2016-12-23 2018-06-28 President And Fellows Of Harvard College Editing of ccr5 receptor gene to protect against hiv infection
CA3050715A1 (en) 2017-01-19 2018-07-26 Open Monoclonal Technology, Inc. Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
TW201839136A (zh) 2017-02-06 2018-11-01 瑞士商諾華公司 治療血色素異常症之組合物及方法
WO2018151514A1 (ko) * 2017-02-16 2018-08-23 고려대학교 산학협력단 골재생 효능이 우수한 골질환 예방 또는 치료용 조성물
US11898179B2 (en) 2017-03-09 2024-02-13 President And Fellows Of Harvard College Suppression of pain by gene editing
CN110662556A (zh) 2017-03-09 2020-01-07 哈佛大学的校长及成员们 癌症疫苗
KR20190127797A (ko) 2017-03-10 2019-11-13 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 시토신에서 구아닌으로의 염기 편집제
WO2018167621A1 (en) * 2017-03-16 2018-09-20 Pfizer Inc. Tyrosine prototrophy
IL269458B2 (en) 2017-03-23 2024-02-01 Harvard College Nucleic base editors that include nucleic acid programmable DNA binding proteins
WO2018209320A1 (en) 2017-05-12 2018-11-15 President And Fellows Of Harvard College Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
JP2020529834A (ja) 2017-06-30 2020-10-15 プレシジョン バイオサイエンシズ，インク． Ｔ細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変ｔ細胞
EP3652320B1 (en) * 2017-07-12 2025-12-24 Mayo Foundation for Medical Education and Research Materials and methods for efficient targeted knock in or gene replacement
WO2019023680A1 (en) 2017-07-28 2019-01-31 President And Fellows Of Harvard College METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE)
BR112020003439A2 (pt) * 2017-08-21 2020-08-25 Tokushima University tecnologia de alteração específica de sequência alvo usando o reconhecimento alvo nucleotídico
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
CN119570864A (zh) * 2017-09-08 2025-03-07 生命技术公司 提高同源重组的方法和其组合物
WO2019079347A1 (en) 2017-10-16 2019-04-25 The Broad Institute, Inc. USES OF BASIC EDITORS ADENOSINE
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
US20210017544A1 (en) * 2017-12-22 2021-01-21 Novozymes A/S Counter-Selection by Inhibition of Conditionally Essential Genes
CN107904208B (zh) * 2017-12-25 2019-11-01 云舟生物科技（广州）有限公司 细胞表型研究用的细胞克隆及其筛选方法和应用
EP3744844A4 (en) 2018-01-23 2021-10-20 Institute for Basic Science EXTENDED SIMPLE RNA GUIDE AND ASSOCIATED USE
BR112020015798A2 (pt) * 2018-02-01 2021-03-09 Homology Medicines, Inc. Composições de vírus adeno-associado para restaurar função de gene da pah e métodos de uso das mesmas
WO2019190990A1 (en) 2018-03-26 2019-10-03 Regeneron Pharmaceuticals, Inc. Humanized rodents for testing therapeutic agents
AU2019252527B2 (en) 2018-04-12 2024-02-22 Precision Biosciences, Inc. Optimized engineered nucleases having specificity for the human T cell receptor alpha constant region gene
EP3788152A4 (en) * 2018-05-04 2022-03-09 Locus Biosciences, Inc. METHODS AND COMPOSITIONS FOR KILLING A TARGET BACTERIA
WO2019222545A1 (en) 2018-05-16 2019-11-21 Synthego Corporation Methods and systems for guide rna design and use
US12157760B2 (en) 2018-05-23 2024-12-03 The Broad Institute, Inc. Base editors and uses thereof
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
WO2020092453A1 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Nucleobase editors comprising geocas9 and uses thereof
WO2020141109A1 (en) * 2018-12-30 2020-07-09 F. Hoffmann-La Roche Ag Method for the selection of cells based on crispr/cas-controlled integration of a detectable tag to a target protein
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
AU2020242032A1 (en) 2019-03-19 2021-10-07 Massachusetts Institute Of Technology Methods and compositions for editing nucleotide sequences
CN113795588B (zh) * 2019-04-04 2025-02-25 瑞泽恩制药公司 用于在靶向性载体中无瘢痕引入靶向修饰的方法
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
BR112022001539A2 (pt) * 2019-05-13 2022-03-22 Rapid Genomics Llc Captura e análise de regiões genômicas alvo
EP4004216A1 (en) * 2019-07-25 2022-06-01 Precision BioSciences, Inc. Compositions and methods for sequential stacking of nucleic acid sequences into a genomic locus
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
WO2021119594A1 (en) * 2019-12-13 2021-06-17 The Regents Of The University Of California Reducing antibiotic resistance in bacteria using pro-active genetics
IL271656A (en) 2019-12-22 2021-06-30 Yeda Res & Dev System and methods for identifying cells that have undergone genome editing
JP2023525304A (ja) 2020-05-08 2023-06-15 ザ ブロード インスティテュート，インコーポレーテッド 標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
TW202208632A (zh) 2020-05-27 2022-03-01 美商同源醫藥公司 用於恢復ｐａｈ基因功能的腺相關病毒組成物及其使用方法
WO2022104344A2 (en) * 2020-11-10 2022-05-19 The Board Of Trustees Of The Leland Stanford Junior University Knock-in of large dna for long-term high genomic expression
CN114763559B (zh) * 2021-01-15 2024-07-19 中国农业大学 一种不依赖于同源重组的靶向性基因捕获系统及其应用
JP2024533683A (ja) * 2021-09-24 2024-09-12 イムノカン バイオテック カンパニー リミテッド 大型染色体の導入方法と改変染色体およびそれを用いた生物
CN121079425A (zh) * 2023-05-10 2025-12-05 武田药品工业株式会社 可再编辑的模板、细胞、组合物和制备方法

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5612205A (en) 1990-08-29 1997-03-18 Genpharm International, Incorporated Homologous recombination in mammalian cells
US5830729A (en) 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
AU8587598A (en) 1997-07-26 1999-02-16 Wisconsin Alumni Research Foundation Trans-species nuclear transfer
DK1015576T3 (da) * 1997-09-16 2005-08-29 Egea Biosciences Llc Fremgangsmåde til fuldstændig kemisk syntese og aggregering af gener og genomer
US6372956B1 (en) 1998-12-31 2002-04-16 The J. David Gladstone Institutes Transgenic rats and rat cell lines expressing human CD4 and a human chemokine receptor
US6599692B1 (en) 1999-09-14 2003-07-29 Sangamo Bioscience, Inc. Functional genomics using zinc finger proteins
US20030104526A1 (en) 1999-03-24 2003-06-05 Qiang Liu Position dependent recognition of GNN nucleotide triplets by zinc fingers
DE60023936T2 (de) 1999-12-06 2006-05-24 Sangamo Biosciences Inc., Richmond Methoden zur verwendung von randomisierten zinkfingerprotein-bibliotheken zur identifizierung von genfunktionen
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20050144655A1 (en) 2000-10-31 2005-06-30 Economides Aris N. Methods of modifying eukaryotic cells
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1341914A2 (en) 2000-12-07 2003-09-10 Sangamo Biosciences Inc. Regulation of angiogenesis with zinc finger proteins
CA2435394C (en) 2001-01-22 2018-01-09 Sangamo Biosciences, Inc. Modified zinc finger binding proteins
WO2002057308A2 (en) 2001-01-22 2002-07-25 Sangamo Biosciences, Inc. Zinc finger polypeptides and their use
AUPR451401A0 (en) 2001-04-20 2001-05-24 Monash University A method of nuclear transfer
US20030082591A1 (en) 2001-07-24 2003-05-01 Donald Awrey Methods for gene disruption and uses thereof
BRPI0307383B1 (pt) 2002-01-23 2019-12-31 The Univ Of Utah Research Foundation método de recombinação genética direcionada em célula de planta hospedeira
WO2003078619A1 (en) 2002-03-15 2003-09-25 Cellectis Hybrid and single chain meganucleases and use thereof
EP1504092B2 (en) 2002-03-21 2014-06-25 Sangamo BioSciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US7612250B2 (en) 2002-07-29 2009-11-03 Trustees Of Tufts College Nuclear transfer embryo formation method
CA2497913C (en) 2002-09-05 2014-06-03 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
WO2004031346A2 (en) 2002-09-06 2004-04-15 Fred Hutchinson Cancer Research Center Methods and compositions concerning designed highly-specific nucleic acid binding proteins
US20030175968A1 (en) 2002-10-30 2003-09-18 Golic Kent G. Gene targeting method
WO2004063356A2 (en) 2003-01-13 2004-07-29 Rao Mahendra S Persistent expression of candidate molecule in proliferating stem and progenitor cells for delivery of therapeutic products
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
EP1591521A1 (en) 2004-04-30 2005-11-02 Cellectis I-Dmo I derivatives with enhanced activity at 37 degrees C and use thereof
CA2579677A1 (en) 2004-09-16 2006-03-30 Sangamo Biosciences, Inc. Compositions and methods for protein production
PT1802193E (pt) 2004-10-19 2014-06-23 Regeneron Pharma Método para gerar um murganho homozigótico para uma modificação genética
FR2879622B1 (fr) 2004-12-17 2008-02-01 Agronomique Inst Nat Rech Procede in vitro de production d'ovocytes ou d'oeufs presentant une modification genomique ciblee
WO2006097854A1 (en) 2005-03-15 2006-09-21 Cellectis Heterodimeric meganucleases and use thereof
WO2006097784A1 (en) 2005-03-15 2006-09-21 Cellectis I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
WO2007005053A1 (en) 2005-06-30 2007-01-11 Codon Devices, Inc. Hierarchical assembly methods for genome engineering
GB0615327D0 (en) 2006-03-30 2006-09-13 Univ Edinburgh Culture medium containing kinase inhibitors and uses thereof
US7910798B2 (en) 2006-03-31 2011-03-22 Medarex, Inc. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
CN101117633B (zh) 2006-08-03 2011-07-20 上海交通大学附属儿童医院 一种细胞核移植方法
ES2586210T3 (es) 2006-12-14 2016-10-13 Sangamo Biosciences, Inc. Proteínas de dedo de zinc no canónicas optimizadas
US7771967B2 (en) 2006-12-22 2010-08-10 The J. David Gladstone Institutes Nucleic acid encoding apolipoprotein E-I3
US8110379B2 (en) 2007-04-26 2012-02-07 Sangamo Biosciences, Inc. Targeted integration into the PPP1R12C locus
SG10201509853UA (en) 2007-06-01 2015-12-30 Omt Inc Compositions and methods for inhibiting endogenous immunoglobulin genes and producing transgenic human idiotype antibodies
CA2708776A1 (en) 2007-12-10 2009-06-18 Aliva Biopharmaceuticals, Inc. Methods for sequential replacement of targeted region by homologous recombination
JP5681114B2 (ja) 2008-12-04 2015-03-04 サンガモ バイオサイエンシーズ， インコーポレイテッド 亜鉛フィンガーヌクレアーゼを使用したラットのゲノム編集
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
US20110239315A1 (en) 2009-01-12 2011-09-29 Ulla Bonas Modular dna-binding domains and methods of use
WO2010107493A2 (en) 2009-03-20 2010-09-23 Sangamo Biosciences, Inc. Modification of cxcr4 using engineered zinc finger proteins
WO2010127111A1 (en) 2009-04-30 2010-11-04 The Trustees Of Comlumbia University In The City Of New York In vivo assembly of dna via homologous recombination
US8772008B2 (en) 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
NZ597481A (en) * 2009-07-08 2013-10-25 Kymab Ltd Animal models and therapeutic molecules
WO2011017293A2 (en) 2009-08-03 2011-02-10 The General Hospital Corporation Engineering of zinc finger arrays by context-dependent assembly
US20120276537A1 (en) 2009-10-28 2012-11-01 Kuehn Ralf Homologous recombination in the oocyte
PT3147362T (pt) 2009-10-29 2019-04-02 Regeneron Pharma Alelos multifuncionais
US20120315670A1 (en) 2009-11-02 2012-12-13 Gen9, Inc. Compositions and Methods for the Regulation of Multiple Genes of Interest in a Cell
JP5807862B2 (ja) 2009-12-01 2015-11-10 国立研究開発法人国立がん研究センター ラット胚性幹細胞を用いたキメララットの作製法
DK2816112T3 (en) 2009-12-10 2018-11-19 Univ Minnesota TAL effector-mediated DNA modification
US20130023051A1 (en) 2009-12-21 2013-01-24 Keygene N.V. Techniques for transfecting protoplasts
US9695432B2 (en) 2010-01-22 2017-07-04 Dow Agrosciences Llc Excision of transgenes in genetically modified organisms
EP2660318A1 (en) 2010-02-09 2013-11-06 Sangamo BioSciences, Inc. Targeted genomic modification with partially single-stranded donor molecules
GB201009732D0 (en) 2010-06-10 2010-07-21 Gene Bridges Gmbh Direct cloning
US9149026B2 (en) 2010-06-11 2015-10-06 Regeneron Pharmaceuticals, Inc. Production of fertile XY animals from XY ES cells
SG186238A1 (en) * 2010-06-17 2013-01-30 Kymab Ltd Animal models and therapeutic molecules
WO2012012667A2 (en) 2010-07-21 2012-01-26 Sangamo Biosciences, Inc. Methods and compositions for modification of a hla locus
WO2012018726A1 (en) * 2010-08-02 2012-02-09 Cellectis Sa Method for increasing double-strand break-induced gene targeting
WO2012129198A1 (en) 2011-03-23 2012-09-27 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for obesity and diabetes
US9113616B2 (en) * 2011-10-28 2015-08-25 Regeneron Pharmaceuticals, Inc. Genetically modified mice having humanized TCR variable genes
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
AU2013251558B2 (en) 2012-04-25 2019-01-03 Regeneron Pharmaceuticals, Inc. Nuclease-mediated targeting with large targeting vectors
JP6559063B2 (ja) 2012-05-07 2019-08-14 サンガモ セラピューティクス， インコーポレイテッド 導入遺伝子のヌクレアーゼ媒介標的化組み込みのための方法および組成物
RS59199B1 (sr) 2012-05-25 2019-10-31 Univ California Metode i jedinjenja za rnk-upravljanu ciljanu dnk modifikaciju i za rnk- upravljanu modulaciju transkripta
CN110066775B (zh) 2012-10-23 2024-03-19 基因工具股份有限公司 用于切割靶dna的组合物及其用途
ES2757325T3 (es) 2012-12-06 2020-04-28 Sigma Aldrich Co Llc Modificación y regulación del genoma en base a CRISPR
IL300461A (en) 2012-12-12 2023-04-01 Harvard College Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
US8697359B1 (en) * 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
RU2721275C2 (ru) 2012-12-12 2020-05-18 Те Брод Инститьют, Инк. Доставка, конструирование и оптимизация систем, способов и композиций для манипуляции с последовательностями и применения в терапии
EP3825401A1 (en) * 2012-12-12 2021-05-26 The Broad Institute, Inc. Crispr-cas component systems, methods and compositions for sequence manipulation
CA2895155C (en) 2012-12-17 2021-07-06 President And Fellows Of Harvard College Rna-guided human genome engineering
EP3491915B1 (en) 2012-12-27 2023-05-31 Keygene N.V. Method for inducing a targeted translocation in a plant.
CN109913495B (zh) 2013-02-20 2022-11-25 瑞泽恩制药公司 大鼠的遗传修饰
JP2016507244A (ja) 2013-02-27 2016-03-10 ヘルムホルツ・ツェントルム・ミュンヒェン・ドイチェス・フォルシュンクスツェントルム・フューア・ゲズントハイト・ウント・ウムベルト（ゲーエムベーハー）Ｈｅｌｍｈｏｌｔｚ Ｚｅｎｔｒｕｍ ＭｕｅｎｃｈｅｎＤｅｕｔｓｃｈｅｓ Ｆｏｒｓｃｈｕｎｇｓｚｅｎｔｒｕｍ ｆｕｅｒ Ｇｅｓｕｎｄｈｅｉｔ ｕｎｄ Ｕｍｗｅｌｔ （ＧｍｂＨ） Ｃａｓ９ヌクレアーゼによる卵母細胞における遺伝子編集
WO2014143381A1 (en) 2013-03-09 2014-09-18 Agilent Technologies, Inc. Methods of in vivo engineering of large sequences using multiple crispr/cas selections of recombineering events
US9234213B2 (en) * 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
US20140349400A1 (en) 2013-03-15 2014-11-27 Massachusetts Institute Of Technology Programmable Modification of DNA
AU2014235968B2 (en) * 2013-03-21 2018-05-24 Ospedale San Raffaele Srl Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
EP4286517A3 (en) 2013-04-04 2024-03-13 President and Fellows of Harvard College Therapeutic uses of genome editing with crispr/cas systems
SI2986729T1 (sl) 2013-04-16 2019-02-28 Regeneron Pharmaceuticals, Inc. Ciljana sprememba genoma podgane
EP3730615A3 (en) 2013-05-15 2020-12-09 Sangamo Therapeutics, Inc. Methods and compositions for treatment of a genetic condition
CA2913865C (en) 2013-05-29 2022-07-19 Cellectis A method for producing precise dna cleavage using cas9 nickase activity
CN105555948A (zh) 2013-06-19 2016-05-04 西格马-奥尔德里奇有限责任公司 靶向整合
EP3988649B1 (en) 2013-09-18 2024-11-27 Kymab Limited Methods, cells and organisms
WO2015052231A2 (en) 2013-10-08 2015-04-16 Technical University Of Denmark Multiplex editing system
US10787684B2 (en) 2013-11-19 2020-09-29 President And Fellows Of Harvard College Large gene excision and insertion
CN110951779B (zh) 2013-12-11 2024-04-16 瑞泽恩制药公司 用于靶向修饰基因组的方法和组合物
EP3080275B1 (en) 2013-12-13 2020-01-15 Cellectis Method of selection of transformed diatoms using nuclease
WO2015116969A2 (en) 2014-01-30 2015-08-06 The Board Of Trustees Of The University Of Arkansas Method, vectors, cells, seeds and kits for stacking genes into a single genomic site
WO2015163733A1 (en) 2014-04-24 2015-10-29 Institute For Basic Science A method of selecting a nuclease target sequence for gene knockout based on microhomology
GB201407852D0 (en) 2014-05-02 2014-06-18 Iontas Ltd Preparation of libraries od protein variants expressed in eukaryotic cells and use for selecting binding molecules
DK3152312T3 (da) 2014-06-06 2020-04-06 Regeneron Pharma Fremgangsmåder og sammensætninger til modifikation af et mållocus
JP6752158B2 (ja) 2014-06-26 2020-09-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 標的化された遺伝子修飾のための方法及び組成物、並びに使用方法
ES2741387T3 (es) 2014-10-15 2020-02-10 Regeneron Pharma Métodos y composiciones para generar o mantener células pluripotentes
ES3013183T3 (en) 2014-11-21 2025-04-11 Regeneron Pharma Methods for targeted genetic modification using paired guide rnas
CN107208113A (zh) 2014-12-19 2017-09-26 瑞泽恩制药公司 用于通过单步多重靶向进行靶向遗传修饰的方法和组合物
GB201504223D0 (en) 2015-03-12 2015-04-29 Genome Res Ltd Biallelic genetic modification
US20200392538A1 (en) 2017-08-30 2020-12-17 President And Fellows Of Harvard College Iterative genome assembly

Also Published As

Publication number Publication date
US10106820B2 (en) 2018-10-23
RU2704283C9 (ru) 2020-02-07
CA2950173A1 (en) 2015-12-10
EP3708671A1 (en) 2020-09-16
SG11201609634YA (en) 2016-12-29
MX2016016133A (es) 2017-08-04
JP2020137521A (ja) 2020-09-03
DK3152312T3 (da) 2020-04-06
US20240352489A1 (en) 2024-10-24
EP3152312A1 (en) 2017-04-12
ES2784754T3 (es) 2020-09-30
CY1122897T1 (el) 2021-05-05
IL249042A0 (en) 2017-01-31
SG10201913804WA (en) 2020-03-30
CN106795521A (zh) 2017-05-31
CN106795521B (zh) 2021-06-04
KR20170027743A (ko) 2017-03-10
KR102374379B1 (ko) 2022-03-17
RU2016150168A (ru) 2018-07-18
AU2015269187A2 (en) 2017-01-19
SI3152312T1 (sl) 2020-07-31
US20190225992A1 (en) 2019-07-25
ES3019688T3 (en) 2025-05-21
CN113215196A (zh) 2021-08-06
CA2950173C (en) 2023-10-10
PL3152312T3 (pl) 2020-08-10
US20170211099A1 (en) 2017-07-27
US20150376650A1 (en) 2015-12-31
RS60359B1 (sr) 2020-07-31
AU2015269187A1 (en) 2017-01-12
WO2015188109A1 (en) 2015-12-10
HUE049776T2 (hu) 2020-10-28
PT3152312T (pt) 2020-04-23
NZ727481A (en) 2023-06-30
US12060571B2 (en) 2024-08-13
LT3152312T (lt) 2020-04-27
IL249042B (en) 2021-09-30
JP7154248B2 (ja) 2022-10-17
RU2016150168A3 (hr) 2018-12-05
JP6688231B2 (ja) 2020-04-28
RU2704283C2 (ru) 2019-10-25
SMT202000264T1 (it) 2020-07-08
CN113215196B (zh) 2024-09-03
EP3152312B1 (en) 2020-02-12
EP3708671B1 (en) 2025-04-02
AU2015269187B2 (en) 2021-06-17
EP3708671C0 (en) 2025-04-02
MX385689B (es) 2025-03-18
JP2017520243A (ja) 2017-07-27
US10294494B2 (en) 2019-05-21
BR112016028564A2 (pt) 2018-01-30

Similar Documents

Publication Publication Date Title
HRP20200529T1 (hr) Postupci i pripravci za modificiranje ciljnog lokusa
JP7095066B2 (ja) 単一ステップの複数標的化を通じた標的化された遺伝子修飾のための方法及び組成物
US10301646B2 (en) Nuclease-mediated targeting with large targeting vectors
AU2015349692B2 (en) Methods and compositions for targeted genetic modification using paired guide RNAs
HK40035693A (en) Methods and compositions for modifying a targeted locus
HK1235817A1 (en) Methods and compositions for modifying a targeted locus
HK1235817B (en) Methods and compositions for modifying a targeted locus
RU2019132992A (ru) Способы и композиции для модификации целевого локуса
HK1207396B (en) Nuclease-mediated targeting with large targeting vectors